SCHEMBL21033318

SCHEMBL21033318

Cc1c(C(=O)O)nc2ccc(C(F)(F)F)nn12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.35
PDE4B Q07343 3/20 0.35
AKT1 P31749 1/20 0.35
AKT2 P31751 1/20 0.35
POLB P06746 1/20 0.34
LRRK2 Q5S007 1/20 0.34
PDE10A Q9Y233 1/20 0.34
RIPK1 Q13546 1/20 0.34
KDM4E B2RXH2 3/20 0.33
PTGS2 P35354 2/20 0.33
ALDH1A1 P00352 2/20 0.33
MALT1 Q9UDY8 1/20 0.33
PIN1 Q13526 1/20 0.33
HSD17B10 Q99714 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PDE4A P27815 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30845864 0.87 PDE10A (0.43) PDE4BAKT1AKT2PDE10AKDM4E
SCHEMBL24066285 0.82 PDE4A (0.47) MAPTPOLBKDM4EPTGS2ALDH1A1
SCHEMBL15690090 0.77 PDE4A (0.37) MAPTPDE10AKDM4EPTGS2ALDH1A1
SCHEMBL6619842 0.77 HSD17B10 (0.40) MAPTPDE4BPOLBPDE10AKDM4E
SCHEMBL16765148 0.73 AKT1 (0.37) MAPTPDE4BAKT1AKT2KDM4E
SCHEMBL18365956 0.71 RIPK1 (0.44) MAPTAKT1AKT2LRRK2RIPK1
SCHEMBL9893241 0.71 USP7 (0.43) MAPTPOLBKDM4EPTGS2ALDH1A1
SCHEMBL21033478 0.68 PDE10A (0.33) PDE4BPOLBPDE10AKDM4EALDH1A1
SCHEMBL12425930 0.68 CA12 (0.35) MAPTPDE4BAKT1AKT2POLB
SCHEMBL16764299 0.67 MAPK8 (0.48) MAPTPDE4BPOLBLRRK2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210371431-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS JUBILANT EPISCRIBE LLC 2021-12-02 US disclosed
WO-2019102494-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2019-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210371431-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 MAPT 30/4885PDE4B 925/4885AKT1 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.